恶性星形细胞瘤I期树突状细胞疫苗试验结果：与辅助化疗的潜在相互作用

Results of a phase I dendritic cell vaccine trial for malignant astrocytoma: potential interaction with adjuvant chemotherapy.

作者信息

Walker David G, Laherty Richard, Tomlinson Frank H, Chuah Teong, Schmidt Chris

机构信息

Department of Neurosurgery, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.

出版信息

J Clin Neurosci. 2008 Feb;15(2):114-21. doi: 10.1016/j.jocn.2007.08.007.

DOI:10.1016/j.jocn.2007.08.007

PMID:18083572

Abstract

Dendritic cell vaccination has been applied to the treatment of a variety of cancers, including malignant astrocytoma. We have treated 13 patients with malignant astrocytoma using dendritic cell vaccination and have shown that this treatment is safe and is likely to be effective in combination with standard adjuvant therapy. Future studies should prospectively incorporate dendritic cell vaccination together with chemotherapy. Ideally, dendritic cell vaccination should be tested in a prospective fashion, in a coordinated trial involving multiple centres.

摘要

树突状细胞疫苗接种已应用于多种癌症的治疗，包括恶性星形细胞瘤。我们使用树突状细胞疫苗接种治疗了13例恶性星形细胞瘤患者，并表明这种治疗是安全的，且与标准辅助治疗联合使用可能有效。未来的研究应前瞻性地将树突状细胞疫苗接种与化疗结合起来。理想情况下，树突状细胞疫苗接种应以前瞻性方式在涉及多个中心的协调试验中进行测试。